Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 1, 1996, Pages 105-112

  Modi, Nishit B ^a   Reynolds, Theresa ^a   Baughman, Sharon A ^a   Thomas, Deborah A ^a   Paasch, Brian D ^a   Smith, Susan Y ^b  

^a GENENTECH INC   (United States)

^b Canada Bio Research Laboratoires Ltd   (Canada)

Author keywords

gpIIbIIIa Antagonist; Interaction; Pharmacodynamics; Pharmacokinetics; TP 9201

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG CLEARANCE; DRUG EFFECT; FIBRINOLYTIC THERAPY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ASPIRIN; DOGS; DRUG THERAPY, COMBINATION; HEPARIN; MALE; PEPTIDES, CYCLIC; PLASMINOGEN ACTIVATORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030033884     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199601000-00017     Document Type: Article

References (40)

1. Yasuda T, Gold HK, Kohmura C, et al. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly- Asp-containing platelet GPIIb/IIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arter Thromb 1993;13:738-17.
2. Popma JJ, Topol EJ. Accelerated, combined, and adjunctive thrombolytic strategies for acute myocardial infarction. Curr Opin Cardiol 1990;5:482-9.
3. Coller BS. Platelets and antithrombotic therapy. N Engl J Med 1990;32:33-42.
4. Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with recombinant tissue-type plasminogen activator by treatment with heparin. Circulation 1986;74:583-7.
5. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanine-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988;85:3184-8.
6. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallen JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-25.
7. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988;77:670-7.
8. Shebuski RJ, Stabilito U, Sitko GR, Polokoff MA. Acceleration of recombinant tissue-type plasminogen activator induced thrombolysis and prevention of reocclusion by the combination of heparin and the RGD-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 1990;82:169-77.
9. Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi B. Prevention of rethrombosis after coronary thrombosis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragments. J Cardiovasc Pharmacol 1994;23:194-202.
10. Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, Echistatin, in a canine model of coronary thrombosis. Pharmacology 1991;42:340-8.
11. Rapold HJ, Gold HK, Wu Z, Napier M, Bunting S, Collen D. Effects of G4120, a Arg-Gly-Asp containing synthetic platelet glycoprotein IIb/IIa receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs. Fibrinolysis 1993;7:248-56.
12. Lu HR, Gold HK, Wu Z, et al. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs. Thromb Haemost 1992;67:686-91.
13. Harker LA. Role of platelets and thrombosis in mechanisms of occlusion and restenosis after angioplasty. Am J Cardiol 1987;6020B-8B.
14. Coller BS, Peerschke EL Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins lib and IIIa. J Clin Invest 1983;72:325-38.
15. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979;254:5357-63.
16. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979;64:1393-401.
17. Plow EF. Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987;36:4035-40.
18. Haskel EJ, Adams SP. Feigen LP, et al. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb-IIIa receptors. Circulation 1989;83:1048-56.
19. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin: a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem 1988;263:19827-32.
20. Dennis MS, Henzel WJ, Pitti RM, et al. Platelet GPIIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. Proc Natl Acad Sci USA 1990;87:2471-5.
21. Huang T-F, Wang W-J, Teng C-M, Ouyang C. Mechanism of action of the antiplatelet peptide, arietin, from Bills arietans venom. Biochim Biophys Acta 1991;1074:144-50.
22. Huang T-F, Liu C-Z, Ouyang C, Teng C-M. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist. Biochem Pharmacol 1991; 42:1209-19.
23. Yasuda T, Gold HK. Leinbach RC, et al. Kistrin, a poly-peptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991;83:1038-47.
24. 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. J Lab Clin Med 1994;124:589-99.
25. Yasuda T, Gold HK, Fallen JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988 ;81:1284-91.
26. 2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990;81:617-27.
27. Ellis SG, Tcheng JE, Navetta FI, et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Dis 1993;4:167-75.
28. Cheng S, Craig WS, Mullen D, Tschopp JF, Dixon D, Pierschbacher MD. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin αIIbβ3 antagonists. J Med Chem 1994;37:1-8.
29. Collen D, Lu HR, Stassen J-M, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994;71:95-102.
30. Tschopp JF, Driscoll EM, Mu D-X, Black SC, Pierschbacher MD, Lucchesi BR. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time. Coronary Artery Dis 1993;4:809-17.
31. Panzer-Knodle S, Taite BB, Mehrotra DV, Nicholson NS, Feigen LP. Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. J Pharmacol Methods 1993;30:47-53.
32. Bachas LG, Tsalta CD, Meyerhoff ME. Binding proteins as reagents in enzyme-linked competitive binding assays for biological molecules. BioTechniques 1986;1:42-55.
33. Modi NB, Baughman SA, Paasch BD, Celniker A, Smith SY. Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs. J Cardiovasc Pharmacol 1995;25:888-97.
34. Tanswell P, Koup J. Topfit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int J Clin Pharmacol Ther Toxicol 1993;31:514-20.
35. Perrier D, Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 1982;71:372-3.
36. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989;65:83-94.
37. Rudd MA, George D, Amarante P, Vaughan DE, Loscalzo J. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res 1990;67:1175-81.
38. Ohlstein EH, Storer B, Fujita T, Shebuski RJ. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregabilit y in the rabbit. Thromb Res 1987;46:575-85.
39. Schafer AI, Adelmen B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75:456-61.
40. Torr SR, Winters KJ, Santoro SA, Sobel BE. The nature of interactions between tissue-type plasminogen activator and platelets. Thromb Res 1990;59:279-93.